Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9 (3), 136-43

Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders


Applications of CRISPR/Cas9 for Gene Editing in Hereditary Movement Disorders

Wooseok Im et al. J Mov Disord.


Gene therapy is a potential therapeutic strategy for treating hereditary movement disorders, including hereditary ataxia, dystonia, Huntington's disease, and Parkinson's disease. Genome editing is a type of genetic engineering in which DNA is inserted, deleted or replaced in the genome using modified nucleases. Recently, clustered regularly interspaced short palindromic repeat/CRISPR associated protein 9 (CRISPR/Cas9) has been used as an essential tool in biotechnology. Cas9 is an RNA-guided DNA endonuclease enzyme that was originally associated with the adaptive immune system of Streptococcus pyogenes and is now being utilized as a genome editing tool to induce double strand breaks in DNA. CRISPR/Cas9 has advantages in terms of clinical applicability over other genome editing technologies such as zinc-finger nucleases and transcription activator-like effector nucleases because of easy in vivo delivery. Here, we review and discuss the applicability of CRISPR/Cas9 to preclinical studies or gene therapy in hereditary movement disorders.

Keywords: CRISPR/Cas9; gene editing; gene therapy; hereditary movement disorders.

Conflict of interest statement

The authors have no financial conflicts of interest.

Similar articles

  • RNA-dependent DNA Endonuclease Cas9 of the CRISPR System: Holy Grail of Genome Editing?
    G Gasiunas et al. Trends Microbiol 21 (11), 562-7. PMID 24095303.
    Tailor-made nucleases for precise genome modification, such as zinc finger or TALE nucleases, currently represent the state-of-the-art for genome editing. These nucleases …
  • Genome Editing Using Cas9 Nickases
    AE Trevino et al. Methods Enzymol 546, 161-74. PMID 25398340.
    The RNA-guided, sequence-specific endonuclease Cas9 has been widely adopted as genome engineering tool due to its efficiency and ease of use. Derived from the microbial C …
  • Designed Nucleases for Targeted Genome Editing
    J Lee et al. Plant Biotechnol J 14 (2), 448-62. PMID 26369767. - Review
    Targeted genome-editing technology using designed nucleases has been evolving rapidly, and its applications are widely expanding in research, medicine and biotechnology. …
  • CRISPR/Cas9 Technology as a Potent Molecular Tool for Gene Therapy
    A Karimian et al. J Cell Physiol 234 (8), 12267-12277. PMID 30697727. - Review
    Clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRISPR-Cas9) is an RNA-guided gene editing tool which offers several advantageous …
  • New Variants of CRISPR RNA-guided Genome Editing Enzymes
    J Murovec et al. Plant Biotechnol J 15 (8), 917-926. PMID 28371222. - Review
    CRISPR-mediated genome editing using the Streptococcus pyogenes Cas9 enzyme is revolutionizing life science by providing new, precise, facile and high-throughput tools fo …
See all similar articles

Cited by 1 PubMed Central articles


    1. International Human Genome Sequencing Consortium Finishing the euchromatic sequence of the human genome. Nature. 2004;431:931–945. - PubMed
    1. Jacob HJ. Next-generation sequencing for clinical diagnostics. N Engl J Med. 2013;369:1557–1558. - PubMed
    1. Kim H, Kim JS. A guide to genome engineering with programmable nucleases. Nat Rev Genet. 2014;15:321–334. - PubMed
    1. Olgiati S, Quadri M, Bonifati V. Genetics of movement disorders in the next-generation sequencing era. Mov Disord. 2016;31:458–470. - PubMed
    1. Kumar KR, Lohmann K, Klein C. Genetics of Parkinson disease and other movement disorders. Curr Opin Neurol. 2012;25:466–474. - PubMed